知镜 Cognispect · 医学文献与研究工作台

De Novo Lung Cancer after Lung Transplantation: Rethinking Surveillance and Early Detection.

Mehdizadeh-Shrifi A, Lennartz F, Merhej H, Gottlieb J, Golpon H.
Clinical lung cancer · 2026-10-23 · PMID 43025052

文献摘要

Purpose While lung transplantation (LTx) is an established therapy for end-stage lung disease in an aging population, lung cancer (LC) complicates the transplant journey. This study aimed to elucidate factors associated with LC development and post-diagnosis mortality. Patients and methods We performed a retrospective single-center observational study at a certified lung cancer center of patients with primary LC after LTx between 1997 and 2025. Characteristics, survival and predictors of development of LC and mortality were assessed. Results Of 2,541 LTx recipients, 47 developed LC, corresponding to an incidence of 1.9%. The median time from LTx to LC diagnosis was 6.05 [3.44-8.89] years. Age at transplantation was 55 [IQR 45-59] years; donor age was 52 [46-60] years. Most tumors arose in the transplanted lung (N = 33, 70%). Survival following LC diagnosis was 0.57 [0.22-1.64] years. Unilateral LTx (HR 2.89), donor smoking history (HR 1.82), ILD/pulmonary fibrosis (HR 1.49), older recipient age (HR 1.37 per 10 years), and cumulative recipient smoking exposure (HR 1.13 per 10 pack-years) were associated with LC development. Stage-IV disease (HR 2.56), unilateral LTx (HR 2.13), prolonged time to LC diagnosis (HR 2.09), and advanced donor age (HR 2.03) were associated with mortality. Conclusion Lung cancer after LTx is a rare complication with poor prognosis. Recipient-, donor, and transplant-related characteristics were associated with LC development, while advanced-stage disease and selected transplant-related factors were associated with mortality. Screening protocols should be intensified in an aging LTx population.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。